Helen Valenstein-Mah1,2, Hildi Hagedorn1,3, Chad L Kay4, Melissa L Christopher4, Adam J Gordon5,6,7. 1. a Center for Chronic Disease Outcomes Research , Minneapolis VA Healthcare System , Minneapolis , Minnesota , USA. 2. b Department of Medicine , University of Minnesota Medical School , Minneapolis , Minnesota , USA. 3. c Department of Psychiatry , University of Minnesota Medical School , Minneapolis , Minnesota , USA. 4. d Academic Detailing Service , Pharmacy Benefits Management, VA Central Office , Washington , DC , USA. 5. e Informatics, Decision-Enhancement and Analytic Sciences Center (IDEAS2) and Vulnerable Veteran-Innovative PACT (VIP) Initiative , Salt Lake City VA Health Care System , Salt, Lake City , Utah , USA. 6. f Department of Medicine , University of Utah School of Medicine , Salt Lake City , Utah , USA. 7. g Department of Psychiatry , University of Utah School of Medicine , Salt Lake City , Utah , USA.
Abstract
BACKGROUND: Opioid use disorder (OUD) is a critical concern among US veterans. The Veterans Health Administration (VHA) recommends buprenorphine as a first-line treatment for OUD; however, only 35% of veterans with an OUD currently receive medication treatment. Practical barriers, including the capacity of providers to prescribe, may affect delivery of buprenorphine. We examined the current state of buprenorphine treatment within the VHA. METHODS: National VHA administrative databases were queried to identify all providers credentialed to prescribe buprenorphine as of January 2018. Data were extracted on providers' prescribing capacity (30, 100, or 275 patients concurrently) and number of patients who received buprenorphine in the prior 180 days. RESULTS: A total of 1458 VHA providers were credentialed to prescribe buprenorphine. Forty-three percent of providers had not prescribed buprenorphine to any VHA patients in the past 180 days. Of those that prescribed to at least 1 patient, providers still prescribed to fewer patients than their capacity, regardless of their patient panel size (30, 100, or 275), prescribing to 18.5 patients on average. CONCLUSIONS: VHA providers are prescribing buprenorphine below their capacity. A multipronged approach to increase the number of credentialed providers and address barriers to prescribing is needed to ensure that veterans get effective treatment for OUD.
BACKGROUND: Opioid use disorder (OUD) is a critical concern among US veterans. The Veterans Health Administration (VHA) recommends buprenorphine as a first-line treatment for OUD; however, only 35% of veterans with an OUD currently receive medication treatment. Practical barriers, including the capacity of providers to prescribe, may affect delivery of buprenorphine. We examined the current state of buprenorphine treatment within the VHA. METHODS: National VHA administrative databases were queried to identify all providers credentialed to prescribe buprenorphine as of January 2018. Data were extracted on providers' prescribing capacity (30, 100, or 275 patients concurrently) and number of patients who received buprenorphine in the prior 180 days. RESULTS: A total of 1458 VHA providers were credentialed to prescribe buprenorphine. Forty-three percent of providers had not prescribed buprenorphine to any VHA patients in the past 180 days. Of those that prescribed to at least 1 patient, providers still prescribed to fewer patients than their capacity, regardless of their patient panel size (30, 100, or 275), prescribing to 18.5 patients on average. CONCLUSIONS: VHA providers are prescribing buprenorphine below their capacity. A multipronged approach to increase the number of credentialed providers and address barriers to prescribing is needed to ensure that veterans get effective treatment for OUD.
Entities:
Keywords:
Buprenorphine; opioid use disorder; veterans
Authors: Audrey L Jones; Stefan G Kertesz; Leslie R M Hausmann; Maria K Mor; Ying Suo; Warren B P Pettey; James H Schaefer; Adi V Gundlapalli; Adam J Gordon Journal: J Subst Abuse Treat Date: 2020-02-29
Authors: Evelyn T Chang; Rebecca S Oberman; Amy N Cohen; Stephanie L Taylor; Elisa Gumm; Aram S Mardian; Shawn Toy; Araceli Revote; Britney Lewkowitz; Elizabeth M Yano Journal: J Gen Intern Med Date: 2020-11-03 Impact factor: 5.128
Authors: Scott E Hadland; Victoria A Jent; Rachel H Alinsky; Brandon D L Marshall; Pia M Mauro; Magdalena Cerdá Journal: Am J Prev Med Date: 2020-05-21 Impact factor: 5.043
Authors: Jessica J Wyse; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Amy J Kennedy; Benjamin J Oldfield; Julie R Gaither; Kirsha S Gordon; Melissa Skanderson; Declan T Barry; Kendall Bryant; Stephen Crystal; Amy C Justice; Kevin L Kraemer Journal: AIDS Behav Date: 2021-09-08
Authors: Jayamalathi Priyanka Vakkalanka; Brian C Lund; Stephan Arndt; William Field; Mary Charlton; Marcia M Ward; Ryan M Carnahan Journal: Health Serv Res Date: 2021-12-18 Impact factor: 3.734
Authors: Utibe R Essien; Florentina E Sileanu; Xinhua Zhao; Jane M Liebschutz; Carolyn T Thorpe; Chester B Good; Maria K Mor; Thomas R Radomski; Leslie R M Hausmann; Michael J Fine; Walid F Gellad Journal: J Gen Intern Med Date: 2020-01-21 Impact factor: 5.128
Authors: Irineo Cabreros; Beth Ann Griffin; Brendan Saloner; Adam J Gordon; Rose Kerber; Bradley D Stein Journal: Drug Alcohol Depend Date: 2021-09-22 Impact factor: 4.492
Authors: Amy J Kennedy; Kathleen A McGinnis; Jessica S Merlin; E Jennifer Edelman; Adam J Gordon; P Todd Korthuis; Melissa Skanderson; Emily C Williams; Jessica Wyse; Benjamin Oldfield; Kendall Bryant; Amy Justice; David A Fiellin; Kevin L Kraemer Journal: J Subst Abuse Treat Date: 2021-05-29